Superparamagnetic iron oxide-enhanced magnetic resonance imaging of experimental liver tumors after mitomycin C administration.
The influence of mitomycin C chemotherapy on superparamagnetic iron oxide (SPIO) uptake by the liver was studied in rats (n = 70). This commonly used antineoplastic drug induces a decrease in the phagocytic function of the macrophage-phagocytic system (MPS). The plasma clearance of SPIO measured by relaxometry followed a biexponential model. The fast component half-life increased from 2.9 minutes in controls to 4.5 minutes in mitomycin C-treated animals. The slow component half-life increased from 11.3 to 36.7 minutes. Nevertheless, the magnetic resonance imaging (MRI) diagnostic efficacy 2 hours after infusion of the superparamagnetic agent AMI 25 (n = 10) was as satisfactory in the treated group as in the untreated one. These MRI results were consistent with the relaxometric T2* liver measurements, which were identical in both groups.
Clement
O
O
Département de Radiologie, Hôpital Laennec, Université de Paris V, France.
Frija
G
G
Chambon
C
C
Schouman-Clayes
E
E
D000818:Animals; D003287:Contrast Media; D003911:Dextrans; D052203:Ferrosoferric Oxide; D007501:Iron; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D008297:Male; D016685:Mitomycin / Q000627:therapeutic use*; D009368:Neoplasm Transplantation; D010087:Oxides; D051381:Rats; D011919:Rats, Inbred Strains; D012208:Rhabdomyosarcoma / Q000175:diagnosis* / Q000188:drug therapy
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D016685:Mitomycin; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide